Äèñêóññèîííûé Êëóá Ðóññêîãî Ìåäèöèíñêîãî Ñåðâåðà
MedNavigator.ru - Ïîèñê è ïîäáîð ëå÷åíèÿ â Ðîññèè è çà ðóáåæîì

Âåðíóòüñÿ   Äèñêóññèîííûé Êëóá Ðóññêîãî Ìåäèöèíñêîãî Ñåðâåðà > Äèñêóññèîííûå ôîðóìû > Ðàçíîå

Ðàçíîå Ëþáûå ñîîáùåíèÿ íà ìåäèöèíñêèå òåìû, ïî êîòîðûì íåò îòäåëüíûõ ôîðóìîâ. Ôîðóì: ×àñòíàÿ ïðàêòèêà.

Çàêðûòàÿ òåìà
 
Îïöèè òåìû Ïîèñê â ýòîé òåìå Îïöèè ïðîñìîòðà
  #1516  
Ñòàðûé 10.01.2004, 11:58
Àâàòàð äëÿ TataStar
TataStar TataStar âíå ôîðóìà Ïîë æåíñêèé
çàáàíåí
 
Ðåãèñòðàöèÿ: 05.03.2003
Ãîðîä: Æèòîìèð, âðåìåíàìè Ëîñ-Àëàìîñ
Ñîîáùåíèé: 94
TataStar
Öèòàòà:
Îïóáëèêîâàíî: Zhivov
Òîâ. ãðîìîäîé, ïðèâåäèòå ïîæàëóéñòà ðàáîòû, ãäå ñ ïîìîùüþ êîððåêòíûõ ìåòîäîâ áèîìåäèöèíñêîé ñòàòèñòèêè äîêàçûâàëàñü áû ýôôåêòèâíîñòü ãîìåîïàòè÷åñêîãî ëå÷åíèÿ íó ñêàæåì ïåðèòîíèòà, ìî÷åêàìåííîé áîëåçíè, ïñîðèàçà èëè êàêîé íèáóäü îíêîïàòîëîãèè? Êàê "çíàòîêó" ýòîé ñàìîé ñòàòèñòèêè è ãîìîåïàòó Âàì âèäèìî èíòåðåñíî íàëè÷èå òàêèõ ðàáîò, íå òàê ëè?
À ïîêàæèòå ìíå íîðìàëüíîãî âðà÷à, êîòîðûé â ñòàòèñòèêó íàïèøåò ïðè÷èíó èçëå÷åíèÿ - ãîìåîïàòè÷åñêèå ïðåïàðàòû? Îí òàêîãî íå íàïèøåò, à ó ãîìåîïàòîâ ñòàòèñòèêó íå ñîáèðàþò.
  #1517  
Ñòàðûé 10.01.2004, 13:46
Zhivov Zhivov âíå ôîðóìà
Âåòåðàí ôîðóìà
      
 
Ðåãèñòðàöèÿ: 20.08.2001
Ñîîáùåíèé: 3,792
Zhivov ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåZhivov ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåZhivov ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåZhivov ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåZhivov ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåZhivov ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåZhivov ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåZhivov ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåZhivov ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåZhivov ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåZhivov ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìå
Óâ. TataStar,
×åñòíûé âðà÷ íàïèøåò è ïðèçíàåò âñå êàê áûëî. Åñëè íå âî Ðîññèè, òàê çà Çàïàäå. Áîëåå òîãî èçâåñòíû âïîëíå "îðòîäîêñàëüíûå" âðà÷è, êîòîðûå îêàçàâøèñü â îò÷àÿííîé ñèòóàöèè (íåèçëå÷èìîå îíêîçàáîëåâàíèå) ïûòàëèñü ëå÷èòü ñåáÿ ìåòîäàìè àëüòåðíàòèâíîé ìåäèöèíû. ãëóáîêî èçó÷àëè åå, ïðîàïàãàíäèðîâàëè åå è ÷èòàëè ëåêöèè ïî àëüòåðíàòèâíîé ìåäèöèíå â ñâîåé ñïåöèàëüíîñòè. Îäíàêî, ê ñîæàëåíèþ, àëüòåðíàòèâíàÿ ìåäèöèíà íå ñïàñàëà íè îäíîãî èç íèõ è îíè ñâîèì ïðèìåðîì (ñìåðòüþ) äîêàçàëè åå íåýôôåêòèâåíîñòü â òåõ ñëó÷àÿõ, êîãäà è ìåòîäû íàó÷íî-äîêàçàòåëüíîé ìåäèöèíû áûëè íåýôôåêòèâíû.

Ïî÷åìó ãîìåîïàòû íå âåäóò ñòàòèñòèêó è íå èñïîëüçóþò åå â ñâîèõ "òðóäàõ"? Âî-ïåðâûõ ñóùåñòâóåò íåìàëî ðàáîò çàðóáåæíûõ ãîìåîïòàòîâ, êîòîðûå êàê ðàç èõ âûïîëíÿþò ïî âïîëíå íàó÷íîìó äèçàéíó ñ èñïîëüçîâàíèåì ñòàòèñòèêè. Âî-âòîðûõ, ê ñîæàëåíèþ, áîëüøèíñòâî òàêèõ ðàáîò äåìîíñòðèðóþò íåýôôåêòèâíîñòü ãîìåîïàòèè. Øàìàíû, ìî÷åòåðàïåâòû, êîëäóíû-âåäóíû è ò.ï. òîæå íå ïîëüçóþòñÿ ìàòåìàòè÷åñêèìè ìåòîäàìè â îöåíêå ýôôåêòèâíîñòè ñâîåé ðàáîòû. Ïî÷åìó? Îíè ïðîñòî â áîëüøèíñòâå ñâîåì ñåðûå è íåîáðàçîâàííûå ëþäè, à òî, ÷åì îíè çàíèìàþòñÿ òàêæå äàëåêî îò íàóêè êàê ãàäàíèå íà êàðòàõ Òàðî èëè íà êîôåéíîé ãóùå. Íó à òàì ãäå íå ïàõíåò íàóêîé, ôàêòîì, âîñïðîèçâîäèìîñòüþ ðåçóëüòàòîâ - ñòàòèñòèêà íå íóæíà. Îáìàíûâàòü ëþäåé ìîæíî è áåç ýòîãî, îáìàíûâàòüñÿ ñàìîìó òåì áîëåå. Ôàêò íå íóæåí, íóæíà ñëåïàÿ âåðà âîò è âñå.
  #1518  
Ñòàðûé 10.01.2004, 20:33
YBLOKO
Ãîñòü
 
Ñîîáùåíèé: n/a
ñìåðòü íåðîæäåííûõ

  #1519  
Ñòàðûé 10.01.2004, 21:11
Gromoboy Gromoboy âíå ôîðóìà Ïîë ìóæñêîé
çàáàíåí
 
Ðåãèñòðàöèÿ: 29.05.2003
Ñîîáùåíèé: 237
Gromoboy
Öèòàòà:
Îïóáëèêîâàíî: Zhivov
Áîëåå òîãî èçâåñòíû âïîëíå "îðòîäîêñàëüíûå" âðà÷è, êîòîðûå îêàçàâøèñü â îò÷àÿííîé ñèòóàöèè (íåèçëå÷èìîå îíêîçàáîëåâàíèå) ïûòàëèñü ëå÷èòü ñåáÿ ìåòîäàìè àëüòåðíàòèâíîé ìåäèöèíû. ãëóáîêî èçó÷àëè åå, ïðîàïàãàíäèðîâàëè åå è ÷èòàëè ëåêöèè ïî àëüòåðíàòèâíîé ìåäèöèíå â ñâîåé ñïåöèàëüíîñòè. Îäíàêî, ê ñîæàëåíèþ, àëüòåðíàòèâíàÿ ìåäèöèíà íå ñïàñàëà íè îäíîãî èç íèõ è îíè ñâîèì ïðèìåðîì (ñìåðòüþ) äîêàçàëè åå íåýôôåêòèâåíîñòü â òåõ ñëó÷àÿõ, êîãäà è ìåòîäû íàó÷íî-äîêàçàòåëüíîé ìåäèöèíû áûëè íåýôôåêòèâíû.
À âåäü âðåòå, Æèâîâ. Äàæå çäåñü íà ôîðóìå ä-ð Çàéöåâ öèòèðîâàë:
N Engl J Med 2002; 347:1986, Dec 12, 2002

Living Proof: A Medical Mutiny
By Michael Gearin-Tosh. 334 pp. New York, Scribner, 2002. $25. ISBN 0-7432-2517-1.
This book is an autobiographical account by a classicist and fellow of St. Catherine's College, Oxford, who received a diagnosis of multiple myeloma. He refused conventional medical treatment yet has survived for more than eight years. His case was reviewed by leading oncologists and physicians in Britain and the United States, and it was confirmed that he had stage 1 multiple myeloma. Stage 1 multiple myeloma occupies a borderland between the relatively benign form of the disease, so-called smoldering myeloma, and the aggressive classic form of the disease. It is not uncommon for an oncologist with a practice in myeloma to see a patient with stage 1 myeloma who survives for many years. The treatment offered by conventional medicine to Gearin-Tosh was intensive chemotherapy, with the hope of eradicating the disease and prolonging his life. Another option was simply to keep his condition under careful surveillance, but this is not mentioned in his account of his consultations. After much thought he refused a conventional approach, and with the help of close friends, he explored various alternative, or complementary, therapies.
Why did this intelligent, erudite, and by his own admission, obstreperous man write this book? Journalists seized on it and used it to vilify orthodox medical practice and doctors in general. This was grossly unfair, for Gearin-Tosh does no such thing in his book. He is remarkably even-handed and very perceptive, seeing both the good and bad in both orthodox and alternative approaches. He describes vividly the turmoil and terror at first hearing the diagnosis, and as he looked at the depressing survival curves in the textbooks, one can well imagine his distress at the "terrifying reality." He deals frankly with the intimacies of the medical consultation, which is one of the book's most valuable contributions. Robert Burns said, "O wad some Pow'r the giftie gie us/To see oursels as others see us," and for those of us in the healing professions, Gearin-Tosh shines a bright light on our deficiencies.
There is lively writing about his life, his friends, his love of the stage and literature, and the comfort and support he got from his books. You know that it would have been a privilege to have had him as a tutor. There are interesting reflections on various characters at the university and on that most convoluted system of education, the Oxford collegiate system, which nevertheless supported him in his hour of need.
So Living Proof of what? Having survived, Gearin-Tosh feels he has the right to draw lessons from his experience. He advocates taking time to consider the opinions offered, and certainly nobody could disagree with that. It would have been right to emphasize that this should be done only after a clinical assessment to rule out such devastating complications as incipient paralysis from spinal cord compression and kidney failure, both of which can develop quickly in classic multiple myeloma. I am sure Gearin-Tosh did not wish to give bad advice to others who have received a diagnosis of multiple myeloma, but the publication of the book and its misinterpretation by the press did prompt the United Kingdom branch of the International Myeloma Foundation, an excellent patient-support organization, to respond with a front-page editorial because so many patients and their families had been upset.
Gearin-Tosh's second assertion is that one needs "proof against proof." He believes that patients are very vulnerable and that with the use of statistics, they can be propelled in a direction in which they do not wish to go. He found the evidence in favor of conventional treatment unconvincing and opted for such alternative therapies as Gerson therapy with its strict diet, vitamins, and enemas. High-dose vitamin C and high-dose vitamin D, both contraindicated in the orthodox treatment of multiple myeloma, were later added to the regimen. What is evident is that this was the right therapy for him. He chose it, he has been able to control it, and although it seems far worse than conventional chemotherapy, he has been able to tolerate it and is alive. The irony of the whole situation is that a recent randomized trial of treatment for stage 1 multiple myeloma by Riccardi and colleagues (British Journal of Cancer 2000;82:1254-60) showed no advantage of conventional chemotherapy over no treatment. Would Gearin-Tosh have accepted that proof? I wonder.

James Spencer Malpas , M.D., D.Phil.
St. Bartholomew's Hospital
London EC1A 7BE, United Kingdom

  #1520  
Ñòàðûé 10.01.2004, 22:08
Zhivov Zhivov âíå ôîðóìà
Âåòåðàí ôîðóìà
      
 
Ðåãèñòðàöèÿ: 20.08.2001
Ñîîáùåíèé: 3,792
Zhivov ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåZhivov ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåZhivov ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåZhivov ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåZhivov ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåZhivov ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåZhivov ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåZhivov ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåZhivov ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåZhivov ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåZhivov ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìå
Âñÿ ïðîáëåìà ãðîìîãëàñíûé Åâãåíèé çàêëþ÷àåòñÿ â òîì, ÷òî Âû ïëîõî ïîíèìàåòå àíãëèéñêèé.  îïèñàííîì Âàìè ñëó÷àå (à îäèí ñëó÷àé êðîìå âñåãî ïðî÷åãî íè÷åãî âîîáùå íå äîêàçûâàåò) ÿñíî ãîâîðèòñÿ ñëåäóþùåå Stage 1 multiple myeloma occupies a borderland between the relatively benign form of the disease, so-called smoldering myeloma, and the aggressive classic form of the disease. It is not uncommon for an oncologist with a practice in myeloma to see a patient with stage 1 myeloma who survives for many years.  êîðîòêîì ïåðåâîäå ýòî îçíà÷àåò, ÷òî ìíîæåñòâåííàÿ ìèåëîìà 1-é ñòàäèè ÿâëÿåòñÿ âîîáùå ïîãðàíè÷íûì ñîñòîÿíèåì ìåæäó çëîêà÷åñòâåííûì è îòíîñèòåëüíî äîáðîêà÷åñòâåííûì ïðîöåññîì è îíêîëîãè íåðåäêî âèäÿò áîëüíûõ, êîòîðûå ñ ýòîé ñòàäèåé çàáîëåâàíèÿ æèâóò ìíîãî ëåò. Âïîëíå âåðîÿòíî ÷òî Michael Gearin-Tosh ïðîñòî ïîïàë â ãðóïïó äîáðîêà÷åñòâåííîãî òå÷åíèÿ áîëåçíè è ê åãî ñëó÷àþ ïðîâåäåííàÿ àëüòåðíàòèâíàÿ òåðàïèÿ íèêàêîãî îòíîøåíèÿ íå èìååò. Îí ñ òàêèì æå óñïåõîì ìîã ëå÷èòüñÿ ïèâêîì èëè êóìûñîì çàðÿæåííûì â âàøåì æóëèêîâàòîì Æóðåêå.  êîíöå ïîâåñòâîâàíèÿ ïðîöèòèðîâàíà ðàáîòà, êîòîðàÿ ïîêàçàëà, ÷òî õèìèîòåðàïèÿ íå äàþò ïðåèìóùåñòâ â âûæèâàåìîñòè ïðè Stage 1 multiple myeloma. Òàêîå â îíêîëîãèè áûâàåò òîãäà, êîãäà õèìèîòåðàïèåé ëå÷àò ïðàêòè÷åñêè äîáðîêà÷åñòâåííûé èëè õîðîøî äèôôåðåíöèðîâàííûé (ìåäëåííî ðàçâèâàþùèéñÿ) îïóõîëåâûé ïðîöåññ. Ê ñëîâó ñêàçàòü ÕÒ ïðè çëîêà÷åñòâåííûõ îïóõîëÿõ ÿè÷êà îáåñïå÷èâàåò áëèçêóþ ê 100% âûæèâàåìîñòü ÷åðåç 5 ëåò ïðè îòñóòñâèè î÷åâèäíûõ ìåòàñòàçîâ, è 90% è âûøå äàæå íà ìåòàñòàòè÷åñêèõ ñòàäèÿõ áîëåçíè. Áåç ñâîåâðåìåííûõ îïåðàöèé è ÕÒ òàêèå áîëüíûå ïî÷òè â òåõ æå 100% óìèðàþò â òå÷åíèå 1-1,5 ëåò.

×òî Âû ïûòàëèñü ïðîöèòèðîâàòü çäåñü: N Engl J Med 2002; 347:1986, Dec 12, 2002 ÿ òàê è íå ïîíÿë. Íè àâòîðîâ íåò, íè íàçâàíèÿ ñòàòüè, íè åå êðàòêîãî ñîäåðæàíèÿ, íè ññûëîê íà íåå (÷òîáû ïîñìîòðåòü). Ñðàçó âèäíî, ÷òî Âû ÷èòàåòå òîëüêî áðåäíè Ãàíåìàíà è ñ ìåäèöèíñêîé ëèòåðàòóðîé íå çíàêîìû. Íàó÷èòåñü ïîæàëóéñòà öèòèðîâàòü ïðåæäå ÷åì ñîâàòüñÿ â äèñêóññèè ñ âðà÷àìè. Äà åùå, ïîäó÷èòå àíãëèéñêèé, à òî âåäü ïîçîðèòåñü ïðîñòî íà ãëàçàõ ÷åñòíîãî íàðîäà. Âàì áû ëó÷øå èç ñâîèõ ôîðóìîâ ïî ãîìåîïàòèè è ïð. àõèíåå íå âûëåçàòü, òàì âû ñìîòðèòåñü óìåñòíåå.

Ñ ãðîìîóäàðíî-óáîéíûì ïðèâåòîì òîâ. ýñìèíåö!
  #1521  
Ñòàðûé 10.01.2004, 22:43
Gromoboy Gromoboy âíå ôîðóìà Ïîë ìóæñêîé
çàáàíåí
 
Ðåãèñòðàöèÿ: 29.05.2003
Ñîîáùåíèé: 237
Gromoboy
Öèòàòà:
Îïóáëèêîâàíî: Zhivov
Âïîëíå âåðîÿòíî ÷òî Michael Gearin-Tosh ïðîñòî ïîïàë â ãðóïïó äîáðîêà÷åñòâåííîãî òå÷åíèÿ áîëåçíè è ê åãî ñëó÷àþ ïðîâåäåííàÿ àëüòåðíàòèâíàÿ òåðàïèÿ íèêàêîãî îòíîøåíèÿ íå èìååò.

Âðÿä-ëè ñòîèò ñ÷èòàòü Michael Gearin-Tosh îñëîì. Íàäî ïîëàãàòü îí èìåë âñå îñíîâàíèÿ ïðèáåãíóòü ê àëüòåðíàòèâíîé ìåäèöèíå.
×òî Âû ïûòàëèñü ïðîöèòèðîâàòü çäåñü: N Engl J Med 2002; 347:1986, Dec 12, 2002 ÿ òàê è íå ïîíÿë. Íè àâòîðîâ íåò, íè íàçâàíèÿ ñòàòüè, íè åå êðàòêîãî ñîäåðæàíèÿ, íè ññûëîê íà íåå (÷òîáû ïîñìîòðåòü).
Äà, ïîíèìàíèå íå âñåì äàíî... Ïðîñüáà ê ä-ðó Çàéöåâó ïðîñâåòèòü îòñòàëîãî òîâàðèùà.
Èëè ñàìîìó Æèâîâó çàãëÿíóòü íà 99 ñòð. ýòîé äèñêóññèè.
  #1522  
Ñòàðûé 10.01.2004, 22:56
E.E. Studentsov E.E. Studentsov âíå ôîðóìà
Çàñëóæåííûé ó÷àñòíèê
 
Ðåãèñòðàöèÿ: 29.06.2003
Ãîðîä: New York, USA
Ñîîáùåíèé: 834
Ñêàçàë(à) ñïàñèáî: 2
Ïîáëàãîäàðèëè 6 ðàç(à) çà 4 ñîîáùåíèé
E.E. Studentsov ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåE.E. Studentsov ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåE.E. Studentsov ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåE.E. Studentsov ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåE.E. Studentsov ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåE.E. Studentsov ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåE.E. Studentsov ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåE.E. Studentsov ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåE.E. Studentsov ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåE.E. Studentsov ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåE.E. Studentsov ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìå
Óâàæàåìûé Àëåêñåé Âèêòîðîâè÷,

Äàííàÿ èíôîðìàöèÿ óæå öèòèðîâàëàñü íà ôîðóìå è îáñóæäàëàñü. Ýòî íå ñòàòüÿ, à ðåöåíçèÿ íà êíèãó, îïóáëèêîâàííàÿ â New England Journal of medicine. Àëüòåðíàòèâùèêè óâèäåëè â ýòîé êíèãå ïðîïàãàíäó èõ ìåòîäîâ è ñòàëè èñïîëüçîâàòü å¸ â ðåêëàìíûõ öåëÿõ.  ñâÿçè ñ ÷åì, èçâåñòíûé ïðîôåññîð íàïèñàë ñâîé êîììåíòàðèé. Ôðàçà: "What is evident is that this was the right therapy for him. He chose it, he has been able to control it, and although it seems far worse than conventional chemotherapy, he has been able to tolerate it and is alive." áûëà íå ïîíÿòà, êàê ÿ íè ñòàðàëñÿ å¸ ðàñòîëêoâàòü. Âèäèìî, æèâÿ èëëþçèÿìè, ìîæíî íå çàìå÷àòü ïîñëåäóþùóþ è çàêëþ÷èòåëüíóþ ôðàçó:
"The irony of the whole situation is that a recent randomized trial of treatment for stage 1 multiple myeloma by Riccardi and colleagues (British Journal of Cancer 2000;82:1254-60) showed no advantage of conventional chemotherapy over no treatment. Would Gearin-Tosh have accepted that proof? I wonder."

Ïî ìîåìó, ñìûñë äàííîé ðåöåíçèè êðèñòàëüíî ÿñåí. Íî êîå-êòî âñå æå ñóìåë ïîäóìàòü, ÷òî ïðîôåññîð Malpas ïðîïàãàíäèðóåò êîôåéíûå êëèçìû.

Ñ óâàæåíèåì,
Å. Ñòóäåíöîâ
  #1523  
Ñòàðûé 11.01.2004, 05:35
V. ZAITSEV V. ZAITSEV âíå ôîðóìà Ïîë ìóæñêîé
çàáàíåí
      
 
Ðåãèñòðàöèÿ: 25.07.2001
Ñîîáùåíèé: 3,330
V. ZAITSEV
Î, êàê òðàêòóþò! Íó, ïðÿìî òàêè øåäåâðû îáúåêòèâíîñòè.
Íà ñ÷åò «äîáðîêà÷åñòâåííîñòè». Áûëî áû èíòåðåñíî, è êàê æå ïåðåâåäåò ñëåäóþùóþ ôðàçó Àëåêñåé Âèêòîðîâè÷.
It is not uncommon for an oncologist with a practice in myeloma to see a patient with stage 1 myeloma who survives for many years.
Îñîáåííî ó÷èòûâàÿ, His case was reviewed by leading oncologists and physicians in Britain and the United States, and it was confirmed that he had stage 1 multiple myeloma.
Òàê æå áûë áû èíòåðåñåí ïåðåâîä (òîëüêî òî÷íûé, à íå èíòåðïðåòàöèþ! ) è òðàêòîâêà àáçàöåâ, íà êîòîðûå îáðàòèë âíèìàíèå Åâãåíèé Åâãåíüåâè÷. È ÷òî æå òàì èç íèõ «êðèñòàëüíî ÿñíî»?
È çàîäíî, ÷òî æå óâàæàåìûé ïðîôåññîð ïîäðàçóìåâàåò â àáçàöå ñ êëþ÷åâîé ôðàçîé:
He is remarkably even-handed and very perceptive, seeing both the good and bad in both orthodox and alternative approaches.
  #1524  
Ñòàðûé 11.01.2004, 09:17
E.E. Studentsov E.E. Studentsov âíå ôîðóìà
Çàñëóæåííûé ó÷àñòíèê
 
Ðåãèñòðàöèÿ: 29.06.2003
Ãîðîä: New York, USA
Ñîîáùåíèé: 834
Ñêàçàë(à) ñïàñèáî: 2
Ïîáëàãîäàðèëè 6 ðàç(à) çà 4 ñîîáùåíèé
E.E. Studentsov ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåE.E. Studentsov ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåE.E. Studentsov ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåE.E. Studentsov ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåE.E. Studentsov ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåE.E. Studentsov ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåE.E. Studentsov ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåE.E. Studentsov ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåE.E. Studentsov ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåE.E. Studentsov ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåE.E. Studentsov ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìå
Ôðàçà:
"It is not uncommon for an oncologist with a practice in myeloma to see a patient with stage 1 myeloma who survives for many years."

Ïåðåâîäèòñÿ êàê:
" Äëÿ îíêîëîãà, çàíèìàþùåãîñÿ ëå÷åíèåì ìèåëîìû, äëèòåëüíàÿ âûæèâàåìîñòü áîëüíûõ ñ ìèåëîìîé ïåðâîé ñòàäèè ÍÅ ÿâëÿåòñÿ ðåäêèì íàáëþäåíèåì."

Íàäåþñü, òåïåðü âñ¸ âñòàíåò íà ñâîè ìåñòà.

Å.Å. Ñòóäåíöîâ
  #1525  
Ñòàðûé 11.01.2004, 14:50
V. ZAITSEV V. ZAITSEV âíå ôîðóìà Ïîë ìóæñêîé
çàáàíåí
      
 
Ðåãèñòðàöèÿ: 25.07.2001
Ñîîáùåíèé: 3,330
V. ZAITSEV
Åâãåíèé Åâãåíüåâè÷!
Ñîãëàñåí ñ ïåðåâîäîì ýòîé ôðàçû, íî ìåäëåííîå ïðîãðåññèðîâàíèå áîëåçíè âñå æå íå ñòîèò íàçûâàòü "äîáðîêà÷èâàåìîñòüþ". Ýòî â ëþáîì ñëó÷àå îíêîëîãè÷åñêîå çàáîëåâàíèå. Êðîìå òîãî, ïðîô Ìàéêë Ãåàðèí-Òîø íè ïðîñòî ïðîæèë åù¸ áîëåå âîñüìè ëåò îò íà÷àëà ëå÷åíèÿ è æèâ äî ñèõ ïîð (à âîò òàêèå ñðîêè äàæå äëÿ ìåäëåííî ïðîãðåññèðóþùåãî òàêîãî çàáîëåâàíèÿ - ðåäêîñòü), à ïîâåðíóë âñïÿòü êëèíè÷åñêèå ïðîÿâëåíèÿ áîëåçíè. Ïî êðàéíåé ìåðå, ó íåãî íå íàáëþäàþòñÿ äàëüíåéøèå ïîðàæåíèÿ êîñòåé, íàðóøåíèÿ ôóíêöèè èììóíèòåòà, èçìåíåíèé â ïî÷êàõ. Âàì âåäü íå òðóäíî îòêðûòü îáñóæäàåìóþ êíèãó , à óæå ïîòîì äåëàòü îêîí÷àòåëüíûå âûâîäû? È ê àëüòåðíàòèâíûì ìåòîäèêàì åãî ïîäâèíóëè, êàê ðàç ñòàòèñòè÷åñêèå äàííûå "óãíåòàþùèå êðèâûå âûæèâàíèÿ" ïðè ýòîì çàáîëåâàíèè.
Ìîæåò áóäåòå ïîñëåäîâàòåëüíû è ïåðåâåäèòå òî÷íî òàê æå òîò àáçàö, íà êîòîðûé ñàìè îáðàòèëè âíèìàíèå, à çàîäíî òó ôðàçó èçâåñòíîãî îíêîëîãà, êîòîðóþ îòìåòèë ÿ?
Òî÷íî òàêæå è â äàëüíåéøåì, ïîæàëóéñòà, äëÿ îáúåêòèâíîñòè, íå âûäåðãèâàéòå òîëüêî òî, ÷òî Âàì, êàæåòñÿ, óêëàäûâàåòñÿ â Âàøè ïðåäñòàâëåíèÿ, çàìàë÷èâàÿ, çàáûâàÿ âñå òî, ÷òî äëÿ Âàøåé êîíöåïöèè íå âûãîäíî.
  #1526  
Ñòàðûé 17.01.2004, 13:30
Àâàòàð äëÿ TataStar
TataStar TataStar âíå ôîðóìà Ïîë æåíñêèé
çàáàíåí
 
Ðåãèñòðàöèÿ: 05.03.2003
Ãîðîä: Æèòîìèð, âðåìåíàìè Ëîñ-Àëàìîñ
Ñîîáùåíèé: 94
TataStar
Öèòàòà:
Îïóáëèêîâàíî: Zhivov
[b]Óâ. TataStar,
×åñòíûé âðà÷ íàïèøåò è ïðèçíàåò âñå êàê áûëî. Åñëè íå âî Ðîññèè, òàê çà Çàïàäå. Áîëåå òîãî èçâåñòíû âïîëíå "îðòîäîêñàëüíûå" âðà÷è, êîòîðûå îêàçàâøèñü â îò÷àÿííîé ñè Îäíàêî, ê ñîæàëåíèþ, àëüòåðíàòèâíàÿ ìåäèöèíà íå ñïàñàëà íè îäíîãî èç íèõ è îíè ñâîèì ïðèìåðîì (ñìåðòüþ) äîêàçàëè åå íåýôôåêòèâåíîñòü â òåõ ñëó÷àÿõ, êîãäà è ìåòîäû íàó÷íî-äîêàçàòåëüíîé ìåäèöèíû áûëè íåýôôåêòèâíû.
Óâàæàåìûé ä-ð Àëåêñåé Æèâîâ.
Ê ñ÷àñòüþ, Âû îøèáàåòåñü. Âàø âçãëÿä âî ñòîðîíû ïðîôåññèîíàëüíîãî âðà÷à - âçãëÿä ÷åðåç îôèöèàëüíóþ ñòàòèñòèêó. Íà ñàìîì äåëå êóäà êàê ÷àùå âñòå÷àåøü ïðîôåññèîíàëüíîãî âðà÷à- ðàçâàëèíó, íåñïîñîáíóþ ïîääåðæèâàòü ñâîå òåëî â çäðàâèè. è ïðè÷èíà òîìó - óâåðåííîñòü â ïðàâèëüíîñòè îôèöèàëüíûõ ìåäèöèíñêèõ çíàíèé. È ìèëëèîíû ëþäåé ñ äðóãóîé ñòîðíû, âûë÷èâøèõñÿ ïðè ïîìîùè ãîìåîïàòèè, íî íå ïîïàâøèõ â îôèöèàëüíóþ ñòàòèñòèêó. Áóäåì ðàññóæäàòü ëîãè÷íî, åñëè ÿ íå ïîëó÷èâ ïîìîùè ó îôèöèàëüíîãî âðà÷à, ïîëó÷èëà åå ó ãîìåîïàòà, ïîéäó ëè ÿ îáðàòíî ëèøü äëÿ òîãî, ÷òîáû ñîîáùèòü ÷òî ìíå óæå íå íóæíà ìåäèöèíñêàÿ ïîìîùü?
Ëè÷íî ÿ èìåëà âîçìîæíîñòü âûñëóøàòü â òàêîì ñëó÷àå âåðäèêòêò îôèöèàëüíîãî âðà÷à - "Âû âûéãðàëè ìåðñåäåñ ïî òðàìâàéíîìó áèëåòó". Íåóæåëè ÿ ïîñëå ýòîãî êîãäà - ëèáî ïîéäó çà ïîìîùüþ ê ýòîìó âðà÷ó?
Íî åãî ÿ íå îáâèíÿþ â íåêîìïåòåíòíîñòè. Âñÿ ïðîáëåìà â òîì, ÷òî îí ïðîôåññèîíàë â ðàìêàõ ñîâðåìåííîãî ñîñòîÿíèÿ ìåäèöèíû. È ïîêà ìåäèöèíñêàÿ íàóêà èñïîüçóåò ïîääåëüíóþ ñòàòèñòèêó, îíà òàê è îñòàíåòñÿ ëæåíàóêîé.
  #1527  
Ñòàðûé 17.01.2004, 15:30
Àâàòàð äëÿ Melnichenko
Melnichenko Melnichenko âíå ôîðóìà
ÂÐÀ×
      
 
Ðåãèñòðàöèÿ: 26.07.2001
Ãîðîä: Ìîñêâà
Ñîîáùåíèé: 117,264
Ñêàçàë(à) ñïàñèáî: 26
Ïîáëàãîäàðèëè 33,619 ðàç(à) çà 32,693 ñîîáùåíèé
Melnichenko ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåMelnichenko ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåMelnichenko ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåMelnichenko ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåMelnichenko ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåMelnichenko ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåMelnichenko ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåMelnichenko ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåMelnichenko ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåMelnichenko ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåMelnichenko ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìå
Òàòà , à êàê , ïî Âàøåìó , âûãëÿäèò ñòàòèñòèêà ? Ò.å êàê ðåàëüíî îñóùåñòâëÿåòñÿ ó÷åò çàáîëåâàíèé \ èçëå÷åíèé ?×òî òàêîå " ïîääåëüíàÿ ñòàòèñòèêà" ?
__________________
Ã.À. Ìåëüíè÷åíêî
  #1528  
Ñòàðûé 18.01.2004, 18:56
Zhivov Zhivov âíå ôîðóìà
Âåòåðàí ôîðóìà
      
 
Ðåãèñòðàöèÿ: 20.08.2001
Ñîîáùåíèé: 3,792
Zhivov ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåZhivov ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåZhivov ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåZhivov ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåZhivov ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåZhivov ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåZhivov ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåZhivov ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåZhivov ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåZhivov ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåZhivov ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìå
Âàø âçãëÿä âî ñòîðîíû ïðîôåññèîíàëüíîãî âðà÷à - âçãëÿä ÷åðåç îôèöèàëüíóþ ñòàòèñòèêó.
Òàòà, ñòàòèñòèêà è ó÷åò çàáîëåâàíèé/èõ èñõîäîâ øòóêà î÷åíü äîðîãàÿ è òðóäîåìêàÿ.  ýòîé ñâÿçè èñ÷åðïûâàþùåé ñòàòèñòèêè â Ðîññèéñêîé ìåäèöèíå ïðîñòî íåò. Ïðèõîäèòñÿ íàì áåäîëàãàì îðèåíòèðîâàòüñÿ ïî áîëüøåé ÷àñòè íà ñòàòèñòèêó çàïàäíóþ. Ïî÷åìó íà çàïàäå âðóò ãîðàçäî ìåíüøå? Îòâå÷àþ. Òàì ñóùåñòâóþò çàêîíû è ãðàæäàíñêîå îáùåñòâî â öåíòðå êîòîðîãî ×ÅËÎÂÅÊ È ÅÃÎ ÍÀÑÓÙÍÛÅ ÈÍÒÅÐÅÑÛ!!! È åñëè ýòî îáùåñòâî çàìåòèò, ÷òî èíòåðåñû ÷åëîâåêà êòî-ëèáî ïîïèðàåò (à âðàíüå â îáëàñòè ìåäèöèíûýòî ÿâëÿåòñÿ îäíèì èç òÿæåëûõ ïðåñòóïëåíèé ïðîòèâ ÷åëîâåêà), ïðîèçîéäåò ñêàíäàë âñåëåíñêîãî ìàñøòàáà è ýòà "âðóùàÿ" ìåäèöèíà ïðîñòî ïðåêðàòèò ñâîå ñóùåñòâîâàíèå è ñàìà ñîáîé çàìåíèòñÿ íà "ïðàâäèâóþ" è áîëåå ýôôåêòèâíóþ. Ïîêà æå â çàïàäíûõ ñòðàíàõ íà ñëóõó òîëüêî ñêàíäàëû âîêðóã àëüòåðíàòèâíûõ ïðàêòèêîâ, êîòîðûõ âñå ÷àùå óëè÷àþò â æóëüíè÷åñòâå. Ìíîãî è äåë ïðîòèâ "îôèöèàëüíûõ" âðà÷åé, íî âñå îíè ñâÿçàíû ñ îøèáêàìè, êîòîðûå â äåÿòåëüíîñòè ÷åëîâåêà íå ðåäêîñòü.

ß òàêæå íå ìîãó çàêðûòü ãëàçà è íà ñâîé îïûò. Ó ìåíÿ èìååòñÿ íå îäèí óæå íàâåðíîå äåñÿòîê ïàöèåíòîâ â òî èëè èíîå âðåìÿ îáðàùàâøèõñÿ ê àëüòåðíàòèâíûì öåëèòåëÿì. Ê ñîæàëåíèþ íè ÿ, íè îíè òîëêó îò ýòîãî íå âèäåëè. Çà èñêëþ÷åíèåì ïîæàëóé ñëó÷àåâ. êîòîðûå âïîëíå ìîæíî îáúÿñíèòü âåñüìà âîçìîæíûì åñòåñòâåííûì ðàçâèòèåì çàáîëåâàíèÿ, åñëè åãî íå ëå÷èòü.

Íà ñàìîì äåëå êóäà êàê ÷àùå âñòå÷àåøü ïðîôåññèîíàëüíîãî âðà÷à- ðàçâàëèíó, íåñïîñîáíóþ ïîääåðæèâàòü ñâîå òåëî â çäðàâèè. è ïðè÷èíà òîìó - óâåðåííîñòü â ïðàâèëüíîñòè îôèöèàëüíûõ ìåäèöèíñêèõ çíàíèé.
Ýòî êîìó íà êîãî âåçåò. Êîíå÷íî áîëüøèíñòâó íàøèõ êîëëåã ïðîñòî íå íà ÷òî ïîääåðæèâàòü ñåáÿ â äîáðîì çäðàâèè. Òå æå êòî íå òîëüêî õîðîøî ðàáîòàþò, íî è õîðîøî îòäûõàþò, ïðàâèëüíî ïèòàþòñÿ è ïîääåðæèâàþò ñåáÿ â ôîðìå íà ðàçâàëèí ñîâñåì íå ïîõîæè è íà ñîáñòâåííîå çäîðîâüå íå æàëóþòñÿ.

Áóäåì ðàññóæäàòü ëîãè÷íî, åñëè ÿ íå ïîëó÷èâ ïîìîùè ó îôèöèàëüíîãî âðà÷à, ïîëó÷èëà åå ó ãîìåîïàòà
Çíà÷èò Âû ñêîðåå âñåãî áûëè çäîðîâû, âî âñÿêîì ñëó÷àå ñîìàòè÷åñêè.

Íî åãî ÿ íå îáâèíÿþ â íåêîìïåòåíòíîñòè. Âñÿ ïðîáëåìà â òîì, ÷òî îí ïðîôåññèîíàë â ðàìêàõ ñîâðåìåííîãî ñîñòîÿíèÿ ìåäèöèíû.
Òàòà, à îòêóäà Âû çíàåòå ÷òî òàêîå ñîâðåìåííîå ñîñòîÿíèå ìåäèöèíû? Ïîâåðüòå ýòîãî äàæå íà 10% íå çíàþò êàê ìèíèìóì 70% âðà÷åé ê êîòîðûì Âû èìååòå âîçìîæíîñòü îáðàòèòüñÿ. ×òîáû ïðåäñòàâëÿòü ñåáå ÷òî òàêîå ñîâðåìåííàÿ ìåäèöèíà íàäî ó÷èòüñÿ áåç îñòàíîâêè, ïîãëîùàÿ åæåäíåâíî áîëüøèå êîëè÷åñòâà íîâîé èíôîðìàöèè, íåïðåñòàííî àíàëèçèðîâàòü èçâåñòíîå, âñòðå÷àòüñÿ è ñ ïîëíûì ïîíèìàíèåì îáùàòüñÿ ñ êîëëåãàìè ñî âñåãî ìèðà, îáîùàòü è àíàëèçèðîâàòü ñîáñòâåííûé îïûò. Ýòî äîñòóïíî î÷åíü íåìíîãèì, ò.ê. ýòî òðåáóåò êîëîññàëüíîãî âðåìåíè, ñèë è íåìàëûõ ñðåäñòâ. Èìåííî ýòî ÿâëÿåòñÿ îäíîé èç ïðè÷èí äîðîãîâèçíû ìåäèöèíñêèõ óñëóã íà Çàïàäå.

È ïîêà ìåäèöèíñêàÿ íàóêà èñïîüçóåò ïîääåëüíóþ ñòàòèñòèêó, îíà òàê è îñòàíåòñÿ ëæåíàóêîé.
Îïÿòü æå ïîæàëóéñòà ïîêîíêðåòíåå. Ïîæàëóéñòà ïîÿñíèòå ÷òî Âû ïîíèìàåòå ïîä ïîääåëüíîé ñòàòèñòèêîé è ÷òî êîíêðåòíî â ñîñðåìåííîé ìåäèöèíå Âû âèäèòå ëæåíàó÷íîãî?
  #1529  
Ñòàðûé 19.01.2004, 07:59
Àâàòàð äëÿ Aminazinka
Aminazinka Aminazinka íà ôîðóìå
Ìîë÷àëèâîå ïðèâèäåíèå
      
 
Ðåãèñòðàöèÿ: 25.12.2003
Ãîðîä: Ìîñêâà
Ñîîáùåíèé: 19,908
Ïîáëàãîäàðèëè 620 ðàç(à) çà 557 ñîîáùåíèé
Aminazinka ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåAminazinka ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåAminazinka ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåAminazinka ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåAminazinka ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåAminazinka ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåAminazinka ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåAminazinka ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåAminazinka ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåAminazinka ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåAminazinka ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìå
Óâàæàåìàÿ Tata!
Âû êîãäà-íèáóäü ñëûøàëè îá ýôôåêòå ïëàöåáî? ÂÎçìîæíî, ÷òî Âû ñëûøàëè òàêæå, ÷òî âíîðìå îêîëî 30% ïàöèåíòîâ ñ ËÞÁÎÉ ÏÀÒÎËÎÃÈÅÉ ðåàãèðóþò íà ïëàöåáî, êàê íà ëåêàðñòâî ñ íåèçâåñòíûìè ñâîéñòâàìè, à èìåííî èçëå÷åíèåì çàáîëåâàíèÿ? Äî ñèõ ïîð íå íàéäåíî ëåêàðñòâ îò èõòèîçà, à òåì íå ìåíåå åñòü â Øòàòàõ äîêòîð, êîòîðûé îäíàæäû (ïî íåçíàíèþ, ïðîñòî âåðèë, ÷òî áîðîäàâêè ëå÷èò) èçëå÷èë áîëüíîãî èõòèîçîì ñ ïîìîùüþ ãèïíîçà? ×òî, ãèïíîòèçåðàì ïàìÿòíèê ñòàâèòü? Äà âñåì âðà÷àì åñòü çà ÷òî ìåäàëè äàâàòü...Äðóãàÿ ñòîðîíà: à Âû íå â êóðñå ñëó÷àéíî, òåõíîëîãèè èçãîòîâëåíèÿ ãîìåîïàòè÷åñêèõ ñðåäñòâ? À â èçëîæåíèè òîâ. Ãàíåìàíà? ß-òî â êóðñå, ïåðâîèñòî÷íèê ÷èòàëà...È ïîïðîáóéòå ìíå äîêàçàòü, ÷òî ãîìåîïàòèÿ - íå ïñèõîòåðàïèÿ ñ øèðî÷àéøèì è äîñòàòî÷íî ïðèáûëüíûì ïðèìåíåíèåì ïëàöåáî...
__________________
Lead, follow, or get out of the way. — Thomas Paine
  #1530  
Ñòàðûé 19.01.2004, 22:54
Zhivov Zhivov âíå ôîðóìà
Âåòåðàí ôîðóìà
      
 
Ðåãèñòðàöèÿ: 20.08.2001
Ñîîáùåíèé: 3,792
Zhivov ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåZhivov ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåZhivov ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåZhivov ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåZhivov ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåZhivov ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåZhivov ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåZhivov ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåZhivov ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåZhivov ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåZhivov ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìå
Ñîâåðøåííî ñ Âàìè ñîãëàñåí Aminazinka
Çàêðûòàÿ òåìà



Âàøè ïðàâà â ðàçäåëå
Âû íå ìîæåòå ñîçäàâàòü òåìû
Âû íå ìîæåòå îòâå÷àòü íà ñîîáùåíèÿ
Âû íå ìîæåòå ïðèêðåïëÿòü ôàéëû
Âû íå ìîæåòå ðåäàêòèðîâàòü ñîîáùåíèÿ

BB êîäû Âêë.
Ñìàéëû Âêë.
[IMG] êîä Âêë.
HTML êîä Âûêë.



×àñîâîé ïîÿñ GMT +3, âðåìÿ: 23:32.




Ðàáîòàåò íà vBulletin® âåðñèÿ 3.
Copyright ©2000 - 2024, Jelsoft Enterprises Ltd.